Observational studyBMC musculoskeletal disorders2026
Women with spondyloarthritis occurring in the peripartum period develop a singular phenotype.
Observational study in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpondyloarthritis (SpA) has specific features in women and may be triggered by parturition. The peripartum period is marked by musculoskeletal remodelling and IL-17 secreting cell activation to enable childbirth. We therefore hypothesized that peripartum SpA might predominantly involve the entheses and be less dependent on HLA-B27 and TNFα.
methodsWe conducted a retrospective, observational, case-control study using the Rouen University Hospital's clinical data warehouse. Delivery dates and symptom onset were available for 154 women with SpA. Characteristics were compared between cases (with peripartum SpA) and controls.
resultsWe identified 58 cases and 96 controls. HLA-B27 (37.3% vs. 52.3%, p-value: 0.04), anterior chest syndrome (74.1% vs. 54.7%, p-value: 0.012 and psoriasis (37.9% vs. 16.8%, p-value: 0.004 were significantly associated with peripartum SpA. Lower rates of biological inflammatory syndrome at TNFα inhibitor introduction, (22.2% vs. 48.1%, p-value: 0.003), of radiographic sacroiliac damage (4% vs. 18.6%, p-value: 0.012 and of MRI sacroiliitis (30.6% vs. 47.4%, p-value: 0.046 were observed in women with peripartum SpA. Also, a lower retention rate of TNFα inhibitors was observed in women with peripartum SpA, 45.6% at 12 months, versus 71.2% controls (Odd ratio: 2.56 [95% CI: 1.34-4.95]). Multivariate survival analysis found a hazard ratio for TNFα inhibitor discontinuation of 2.43 (95% CI: 1.62-3.65) within the first two years of treatment.
conclusionsOur study highlights a distinct phenotype of peripartum SpA, and a lower retention rate of TNFα inhibitors suggesting a worse response to these class of bDMARD.
trial registrationAs we conducted a retrospective study without health care intervention, no prospective registration was done.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.